13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001920938
Total reported value
$2.7B
$2.7B
70 檔
26.3%
As reported in its official Q1 2024 Form 13F filing, Braidwell LP's tracked investment portfolio stood at $2.7B with 70 total positions.
During Q1 2024, Braidwell LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including GH 0 11-15-27, BBIO 2.5 03-15-27, EXAS 0.375 03-01-28) accounted for 26.3% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GH 0 11-15-27Bond | Guardant Health Inc | Bond | 5.92% | — | — | |
| 2 | BBIO 2.5 03-15-27Bond | Bridgebio Pharma Inc | Bond | 4.71% | — | +18.80% | |
| 3 | EXAS 0.375 03-01-28Bond | Exact Sciences CORP | Bond | 4.29% | — | +9.92% | |
| 4 | NVCR 0 11-01-25Bond | Novocure LTD | Bond | 4.02% | — | — | |
| 5 | APGE | Apogee Therapeutics Inc | Stock-Other | 3.95% | -1.34% | EXIT | |
| 6 | GMED 0.375 03-15-25Bond | Nuvasive Inc | Bond | 3.51% | — | +41.82% | |
| 7 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 3.25% | -0.77% | +2.10% | |
| 8 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.79% | -1.46% | +43.48% | |
| 9 | PCVX | Vaxcyte Inc | Stock-Other | 2.67% | — | -5.99% | |
| 10 | NEO 0.25 01-15-28Bond | Neogenomics Inc | Bond | 2.66% | -2.44% | +57.89% | |
| 11 | DXCM 0.25 11-15-25Bond | Dexcom Inc | Bond | 2.31% | — | +44.44% | |
| 12 | LEGN | Legend Biotech Corp-adr | Stock-Other | 2.25% | — | +121.08% | |
| 13 | INSM 1.75 01-15-25Bond | Insmed Inc | Bond | 2.24% | — | +23.86% | |
| 14 | PODD 0.375 09-01-26Bond | Insulet Corporation | Bond | 2.22% | — | +4.76% | |
| 15 | PEN | Penumbra Inc | Stock-Healthcare | 2.13% | -1.15% | EXIT | |
| 16 | MRVI | Maravai Lifesciences Hldgs-a | Stock-Other | 2.02% | +1.04% | +43.27% | |
| 17 | SRPT 1.25 09-15-27Bond | Sarepta Therapeutics Inc | Bond | 1.91% | — | — | |
| 18 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 1.88% | — | — | |
| 19 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.81% | -0.07% | -20.60% | |
| 20 | IRTC | Irhythm Holdings Inc | Stock-Healthcare | 1.81% | +0.48% | -14.94% | |
| 21 | ALGN | Align Technology Inc | Stock-Healthcare | 1.79% | — | +15.68% | |
| 22 | BBIO 2.25 02-01-29Bond | Bridgebio Pharma Inc | Bond | 1.78% | — | — | |
| 23 | IRWD 1.5 06-15-26Bond | Ironwood Pharmaceuticals | Bond | 1.73% | — | +240.26% | |
| 24 | GH | Guardant Health Inc | Stock-Healthcare | 1.65% | -0.72% | +226.36% | |
| 25 | TVTX 2.5 09-15-25Bond | Travere Therapeutics Inc | Bond | 1.60% | — | — | |
| 26 | CGON | Cg Oncology Inc | Stock-Other | 1.60% | -2.22% | EXIT | |
| 27 | KROS | Keros Therapeutics Inc | Stock-Other | 1.57% | — | -34.10% | |
| 28 | TMDX | Transmedics Group Inc | Stock-Healthcare | 1.46% | +0.41% | +422.11% | |
| 29 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 1.45% | — | — | |
| 30 | GKOS | Glaukos CORP | Stock-Healthcare | 1.37% | +0.32% | +85.65% | |
| 31 | FNAUSD | Paragon 28 Inc | Stock-Other | 1.34% | — | +0.11% | |
| 32 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 1.29% | -0.16% | — | |
| 33 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 1.16% | — | -48.44% | |
| 34 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | Bond | 1.15% | — | — | |
| 35 | ATEC 0.75 08-01-26Bond | Alphatec Holdings Inc | Bond | 1.09% | — | +21.25% | |
| 36 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 1.08% | — | — | |
| 37 | KIDS | Orthopediatrics CORP | Stock-Other | 1.04% | +0.20% | — | |
| 38 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 1.02% | +0.20% | -9.74% | |
| 39 | RLAY | Relay Therapeutics Inc | Stock-Other | 1.00% | — | — | |
| 40 | IRWD | Ironwood Pharmaceuticals Inc | Stock-Other | 0.98% | — | — | |
| 41 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.89% | — | — | |
| 42 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 0.88% | +0.14% | -37.76% | |
| 43 | RGEN | Repligen CORP | Stock-Healthcare | 0.85% | +0.70% | +39.08% | |
| 44 | NVROEUR | Nevro CORP | Stock-Other | 0.83% | — | — | |
| 45 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 0.70% | -0.05% | -45.04% | |
| 46 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.68% | — | — | |
| 47 | TRML | Tourmaline Bio Inc | Stock-Other | 0.67% | — | — | |
| 48 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.67% | — | — | |
| 49 | IRWD 0.75 06-15-24Bond | Ironwood Pharmaceuticals | Bond | 0.64% | — | -46.68% | |
| 50 | HAE 0 03-01-26Bond | Haemonetics CORP | Bond | 0.64% | — | — |
According to official SEC Form 13F filings, Braidwell LP reported a total U.S. public equity portfolio value of $2.7B across 70 disclosed positions in Q1 2024.
During Q1 2024, Braidwell LP's top holdings by market value included GH 0 11-15-27 (5.9%)、BBIO 2.5 03-15-27 (4.7%)、EXAS 0.375 03-01-28 (4.3%). The largest single position, GH 0 11-15-27, represented 5.9% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q1 2024, Braidwell LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.